Application of combination of gambogic acid and sorafenib in preparation of liver cancer treatment medicine

A technology for treating drugs and gambogic acid, applied in the field of biomedicine, can solve the problems of prolonging the survival period and improving the quality of life of patients, lack of first-line treatment plans and drugs, and high heterogeneity

Inactive Publication Date: 2022-05-24
南京芩康医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Multi-targeted kinase inhibitors (including sorafenib, lenvatinib, donafenib, etc.) and oxaliplatin systemic chemotherapy are the current standard first-line treatment for liver cancer, but the objective response rate is still unsatisfactory. Survival rates lowest among common cancers
The rebound lethal reaction and drug resistance of targeted drugs are still the insurmountable bottlenecks in the existing liver cancer treatment, seriously affecting the prolongation of patient survival and the improvement of quality of life
The hete...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of gambogic acid and sorafenib in preparation of liver cancer treatment medicine
  • Application of combination of gambogic acid and sorafenib in preparation of liver cancer treatment medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] The growth inhibitory effect of gambogic acid (GA) combined with sorafenib in HepG2 cells 48H was determined by MTT assay

[0022] MTT solution can be reduced to blue-violet crystalline formazan by mitochondrial dehydrogenase in living cells, DMSO can dissolve formazan, and the color of the formed solution is proportional to cell viability, and cell viability can be detected accordingly. The cells were cultured in a 96-well microtiter plate according to the appropriate cell density. The volume of cells in each well was 100 μl. When the cells adhered and the confluence reached 50%, the medium was aspirated and 100 μl of GA and Sora were added at the specified concentrations. Finni; after the cells that had been administered the drug were placed in the incubator for 48 hours, 20 μl of MTT solution was added to each well; after 4 hours of incubation, the supernatant was removed, and 100 μl of DMSO was added to each well, and placed on a micro-shaker to shake until crystalli...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of gambogic acid and sorafenib in preparation of a medicine for treating liver cancer, and belongs to the technical field of biological medicine. The invention finds that the growth of human hepatocellular carcinoma HepG2 cells can be obviously inhibited by combining gambogic acid (GA) extracted from a natural product gamboge with a first-line targeted therapeutic drug sorafenib for liver cancer. The MTT experiment verifies that the gambogic acid with lower concentration can enhance the liver cancer growth inhibition effect of sorafenib, and the application potential of the combined administration mode in treatment of hepatocellular carcinoma is prompted.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and particularly relates to the application of gambogic acid combined with sorafenib in the preparation of a drug for treating liver cancer. Background technique [0002] Multi-target kinase inhibitors (including sorafenib, lenvatinib, donafenib, etc.) and oxaliplatin system chemotherapy are the existing standard first-line treatment of liver cancer, but the objective response rate is still unsatisfactory, 5 years Survival rates are lowest among common cancers. The rebound lethal reaction and drug resistance of targeted drugs are still insurmountable bottlenecks in existing liver cancer treatment, which seriously affect the prolongation of patients' survival and the improvement of their quality of life. Hepatocellular carcinoma patients in China have high heterogeneity, and most of them gradually evolve into hepatocellular carcinoma from hepatitis B, combined with poor liver function, which ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/44A61K31/352A61P35/00
CPCA61K31/44A61K31/352A61P35/00A61K2300/00
Inventor 魏立彬郭青龙周煜新曹雪君高源葛展虹
Owner 南京芩康医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap